Linagliptin

Pharm Company: * AUROBINDO PHARMA LTD
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Linagliptin Overview

Linagliptin (INN,[2] previously known as BI-1356, marketed under trade names Tradjenta (U.S.) and Trajenta (worldwide)) is a dipeptidyl peptidase-4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2. Once-daily linagliptin was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type 2 diabetes.[3] It is being marketed by Boehringer Ingelheim and Lilly. Contents 1 Medical uses 2 Side effec...

Read more Linagliptin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Linagliptin

Recent Linagliptin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Linagliptin
  • Tablet: 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Linagliptin or a similar ingredient: (5 results)

Related Linagliptin Topics:

trajenta linagliptin
what is deference between istamet and trajenta and side effects...






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA